Latest stories on ORKA
ORKA Reiterated by Guggenheim -- Price Target Maintained at $200
GuruFocus56 · neutralanalyst
ORKA Reiterated by Wedbush -- Price Target Maintained at $165
GuruFocus56 · neutralanalyst
Oruka Therapeutics price target lowered to $105 from $131 at Clear Street
The Fly34 · bearishanalyst
Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis - Slideshow
Seeking Alpha56 · neutralproduct/pr
Oruka Therapeutics rises 14.3%
The Fly64 · neutralgeneral
Oruka’s Psoriasis Treatment Could Generate $7B In Peak Sales, Says Guggenheim – ORKA Stock Heads For Best Day In Over 4 Months
Stocktwits News74 · bullishanalyst
Oruka Therapeutics Rises 11 6
The Fly64 · neutralgeneral
Guggenheim reiterates Oruka Therapeutics stock rating on trial data
Investing.com Analyst Ratings52 · neutralanalyst
Oruka Therapeutics Reports Strong Phase 2b Psoriasis Results
TipRanks74 · bullishproduct/pr
Oruka Therapeutics, Inc. (ORKA) files 8-K
SEC 8-K50 · neutralgeneral
Oruka Therapeutics announces results from EVERLAST trial of ORKA-001
The Fly58 · neutralproduct/pr
Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis
GlobeNewswire74 · bullishproduct/pr
Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis
Business Insider74 · bullishproduct/pr
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026
GlobeNewswire53 · neutralproduct/pr
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026
Business Insider53 · neutralproduct/pr
Oruka Therapeutics: The Psoriasis Market Is Becoming A Barbell, And ORKA-001 Owns The Far End
Seeking Alpha64 · neutralproduct/pr
These 2 Stocks Have Run Circles Around the Magnificent Seven This Year, and Wall Street Says There Is More Upside Ahead
The Motley Fool64 · neutralanalyst
Piper Sandler reiterates Oruka Therapeutics stock rating on pipeline catalysts
Investing.com Analyst Ratings56 · neutralanalyst
Oruka Therapeutics stock price target maintained at $120 by H.C. Wainwright
Investing.com Analyst Ratings56 · neutralanalyst
Oruka falls after updating mid-stage trial data for plaque psoriasis therapy
Seeking Alpha34 · bearishproduct/pr
Oruka Therapeutics ORKA-001 data meet base case, says Clear Street
The Fly63 · neutralproduct/pr
Oruka Therapeutics Shares Fall 5% After Week 28 ORKA-001 Trial Data
InvestorsHub38 · neutralproduct/pr
Oruka Therapeutics stock falls despite positive trial data
Investing.com Markets42 · neutralproduct/pr
Oruka’s ORKA-001 posts rising Week 28 skin-clearance rates with no dosing after Week 4
September 23, 2026
MarketChameleon73 · bullishproduct/pr